Abbott Laboratories is currently valued at a decade low of 17.7 times forward earnings despite strong 13.2% growth in its Medical Devices segment in Q1 2026 and a 54-year dividend streak. Key growth drivers include synergies with Exact Sciences, expansion of CMS continuous glucose monitoring (CGM) reimbursement, and recovery in Nutrition segment margins, which could add $1.27 to $1.73 in earnings per share by 2028-2029. The market underestimates Abbott's commercial leverage and potential upside from distribution synergies and CMS reimbursement expansion, leading to a buy rating with a 12-month target price of $126 and intrinsic value above $150 over multiple years, supported by strong cash flow and dividend growth.
Abbott revealed new data showing a significant rise in diabetic ketoacidosis (DKA) hospitalizations across all age groups in the U.S., especially among children with Type 1 diabetes. DKA, a dangerous condition caused by high ketone levels due to insu...
This monthly series highlights five large-cap, dividend-paying stocks trading at significant discounts compared to their historical norms, selected from over 7,500 U.S.-listed companies. The primary list offers an average yield of 4.2%, with two addi...
A U.S. federal judge ruled that Abbott Laboratories' marketing of PediaSure could reasonably be interpreted as promising height growth, despite the company's claims focusing on general growth. The judge noted product packaging and advertising featuri...
The global market for non-invasive blood glucose monitoring devices, which measure blood sugar without needles, is projected to grow from $34.86 million in 2024 to $340.49 million by 2034, at a CAGR of 25.6%. Growth is fueled by the increasing diabet...
